{"analyses":[{"ciLowerLimit":".772","ciPctValue":"95","ciUpperLimit":".992","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Binomial proportion","paramValue":".931","statisticalMethod":"Binomial proportion","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Decrease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Increase or no change"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"To estimate proportion of patients with MRD reduction after one course of Induction II (cytarabine + daunomycin + etoposide (ADE) + GO), who had no response to first course of induction therapy.","groups":[{"description":"Patients who have no response to one course of induction therapy","id":"OG000","title":"Overall"}],"paramType":"NUMBER","populationDescription":"Out of the 30 patients received ADE + GO treatment, one patient had inevaluable MRD prior to and after the treatment. 29 patients were analyzed. Out of the 29 patients, 10 patients were treated on HDAC arm and 19 patients were treated on LDAC arm.","reportingStatus":"POSTED","timeFrame":"Induction II","title":"Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO","type":"SECONDARY","unitOfMeasure":"Participants"}